Xilio Therapeutics, Inc.
XLO · XNASCIK 1840233fmd_0Z22N157GJ7WHCNP7EPF42MTC4Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 6 | 44 |
| Research and development | 44 | 51 | 59 | 52 | 41 | 56 |
| Total operating expenses | 55 | 75 | 89 | 79 | 67 | 86 |
| Operating income | (55) | (75) | (89) | (79) | (61) | (42) |
| Other non-operating income (expense) | (1) | (1) | 1 | 3 | 2 | 7 |
| Income before taxes | – | – | – | – | (58) | (35) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (58) | (35) |
| Net income | (55) | (76) | (88) | (76) | (58) | (35) |